BriaCell Therapeutics Corp Ordinary Shares - New BCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CA$5.31
- Day Range
- CA$5.38–5.44
- 52-Week Range
- CA$3.68–20.40
- Bid/Ask
- CA$5.33 / CA$5.48
- Shares Outstanding
- 8.70M
- Market Cap
- CA$47.15M
- Volume/Avg
- 506 / 6,806
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company’s targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.briacell.com
Valuation
|
Metric
|
BCT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BCT
Financial Strength
|
Metric
|
BCT
|
|---|---|
Quick Ratio | 7.07 |
Current Ratio | 7.07 |
Interest Coverage | −1,061.15 |
Quick Ratio
BCT
Profitability
|
Metric
|
BCT
|
|---|---|
Return on Assets (Normalized) | −137.09% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −167.49% |
Return on Assets
BCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|gSRTW#J | LOCK|>zz?^ | $123B | |||
| Moderna Inc
MRNA
| LOCK|g<Y$vl> | LOCK|N&d | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|T>jbdP | LOCK|^?Cg& | $78B | |||
| argenx SE ADR
ARGX
| LOCK|J<!m?%% | LOCK|Vb | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$z^nC@h | LOCK|WD | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@FTcZq | LOCK|P>z< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|p!b?JVW | LOCK|??p% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G!r?MT | LOCK|#g> | $22B | |||
| Incyte Corp
INCY
| LOCK|P&<m<% | LOCK|Vw | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<C$%?nh | LOCK|vQ@ | $14B |
United States